Mivacron (Mivacurium)

Mivacurium, the active ingredient in Mivacron, is a non‑depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It produces skeletal muscle relaxation by competitively antagonising acetylcholine at nicotinic receptors, and is employed to facilitate endotracheal intubation, to maintain muscle relaxation during surgical procedures, and as an adjunct to mechanical ventilation in intensive‑care settings.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide.

Mivacurium is a non‑depolarizing neuromuscular blocker used in peri‑operative care to produce skeletal muscle relaxation.

- Facilitation of endotracheal intubation: enables rapid and controlled airway placement. - Muscle relaxation during surgery: provides a stable, flaccid field for operative manipulation. - Adjunct to mechanical ventilation: supports prolonged ventilation by preventing spontaneous breathing efforts.

Mivacurium may cause a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Flushing: transient redness of the skin. - Mild hypotension: temporary drop in blood pressure. - Tachycardia: increased heart rate. - Pruritus: itching sensation. - Nausea: feeling of sickness. - Urticaria: hives or skin rash.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate treatment. - Severe hypotension: marked blood‑pressure fall that may need vasopressor support. - Bronchospasm: airway constriction causing breathing difficulty. - Prolonged neuromuscular blockade: extended muscle paralysis beyond intended duration. - Cardiac arrhythmias: irregular heart rhythms. - Hyperkalemia: elevated serum potassium levels.

When using Mivacron, clinicians should observe several safety measures.

- Assess neuromuscular function: monitor train‑of‑four ratio during administration. - Avoid in patients with known hypersensitivity to mivacurium or related benzylisoquinolinium compounds. - Use with caution in hepatic or renal impairment: altered drug clearance may occur. - Consider dose reduction in the elderly: increased sensitivity to blockade. - Monitor for histamine‑mediated reactions: be prepared to treat hypotension or bronchospasm. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics: potentiate neuromuscular blockade. - Magnesium sulfate: enhances blockade and may cause prolonged paralysis. - Lithium: increases sensitivity to muscle relaxants.

Moderate Interactions (Monitor Closely):\n- Inhalational anesthetics: additive effect on muscle relaxation. - Volatile agents (e.g., sevoflurane): may prolong duration of action. - Beta‑agonists: may reduce the depth of blockade, requiring dose adjustment.